Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA).

These improvements occurred early, at the first post-treatment assessment (Day 14 and Day 28 for ACQ-6 and SGRQ scores, respectively), remained consistent over time, and remained nominally significant compared with placebo over the treatment period ( Table 2 ).

also in 7,732 other papers